<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00806546</url>
  </required_header>
  <id_info>
    <org_study_id>PROT-15-NP101-009</org_study_id>
    <nct_id>NCT00806546</nct_id>
  </id_info>
  <brief_title>An Open-Label Study to Evaluate the Safety of NP101 in the Treatment of Acute Migraine Over Twelve Months</brief_title>
  <acronym>NP101-009</acronym>
  <official_title>An Open-Label Study to Evaluate the Safety of NP101, a Sumatriptan Iontophoretic Transdermal Patch, in the Treatment of Acute Migraine Over 12 Months</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>NuPathe Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Teva Branded Pharmaceutical Products R&amp;D, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will use an open-label design to evaluate the safety of NP101. Adult subjects who&#xD;
      meet the enrollment criteria will be treated with NP101 (sumatriptan succinate iontophoretic&#xD;
      transdermal patch) for acute migraine attacks over a 12 month period.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>February 2009</start_date>
  <completion_date type="Actual">May 2011</completion_date>
  <primary_completion_date type="Actual">May 2011</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Subject Self-examination of Skin Irritation</measure>
    <time_frame>24 hours post patch application</time_frame>
    <description>For each patch application, subjects performed a self-examination of skin irritation using a 5-point scale (0=no redness; 1=minimal skin redness; 2=moderate skin redness with sharp borders; 3=intense skin redness with or without swelling; 4=intense skin redness with blisters or broken skin).</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">514</enrollment>
  <condition>Migraine Disorders</condition>
  <arm_group>
    <arm_group_label>NP101</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>sumatriptan iontophoretic transdermal patch</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>NP101</intervention_name>
    <description>NP101 study patch four hour application</description>
    <arm_group_label>NP101</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Subject is an adult male or female, age range 18 years to 65 years.&#xD;
&#xD;
          -  Subject has a diagnosis of migraine headache, with or without aura, as defined in the&#xD;
             ICHD-II and the diagnosis was made before the age of 50.&#xD;
&#xD;
          -  Subject experiences mild to severe headaches during a migraine attack based on subject&#xD;
             testimony.&#xD;
&#xD;
          -  Subject has at least a one year history of migraine based upon subject testimony.&#xD;
&#xD;
          -  Subject typically experiences at least two migraine headaches per month based on&#xD;
             subject testimony.&#xD;
&#xD;
          -  Subject will be judged to be in good health, based upon the results of a medical&#xD;
             history, physical examination, vital signs, ECG and laboratory profile. Subjects will&#xD;
             not have any clinically significant abnormal laboratory parameters, vital signs or ECG&#xD;
             parameters in order to qualify for enrollment.&#xD;
&#xD;
          -  Female subject of childbearing potential (not surgically sterile or 2 years&#xD;
             postmenopausal) must have a negative pregnancy test at screening and prior to&#xD;
             enrollment.&#xD;
&#xD;
          -  Subject must have a negative drug screen.&#xD;
&#xD;
          -  Subject must be capable of reading and understanding either English or Spanish subject&#xD;
             information materials. Be able to successfully apply a practice patch, carry-out all&#xD;
             subject procedures, and be able to voluntarily sign and date an IC agreement approved&#xD;
             by an IRB.&#xD;
&#xD;
          -  Subject has at least two acceptable patch application sites (upper arms or upper&#xD;
             thighs) that are relatively hair free and has no scars, tattoos, scratches or bruises.&#xD;
&#xD;
          -  In the investigator's opinion the subject is on a stable medication regimen.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Subject has more than 15 headache days per month for any of the three months prior to&#xD;
             screening.&#xD;
&#xD;
          -  Subject has suspected or confirmed cardiovascular disease that contraindicates study&#xD;
             participation.&#xD;
&#xD;
          -  Subject has a history of epilepsy or condition associated with a lowered seizure&#xD;
             threshold.&#xD;
&#xD;
          -  Subject has Raynaud's disease.&#xD;
&#xD;
          -  Subject has a history of basilar or hemiplegic migraines.&#xD;
&#xD;
          -  Subject has a history (within 1 year) or current evidence of drug or alcohol abuse or&#xD;
             dependence.&#xD;
&#xD;
          -  Subject has taken non-triptan serotonergic drugs including SSRIs (including&#xD;
             Wellbutrin), SNRIs, TCAs, MAOIs or preparations containing St. John's Wort within 1&#xD;
             month prior to screening and/or is planning to start any of these medications during&#xD;
             the study.&#xD;
&#xD;
          -  Subject is unwilling to discontinue use of a PD5 inhibitor (e.g. Viagra®, Levitra®, or&#xD;
             Cialis®) through the Final Visit.&#xD;
&#xD;
          -  Subject has a history of a significant allergy or hypersensitivity to any component of&#xD;
             the study patch used in this study.&#xD;
&#xD;
          -  Subject has any generalized skin irritation or disease including eczema, psoriasis,&#xD;
             melanoma, or contact dermatitis that would affect transdermal absorption of&#xD;
             sumatriptan and / or affect the subjects ability to assess skin irritation.&#xD;
&#xD;
          -  Subject has clinically significant abnormal laboratory parameters, vital signs or ECG&#xD;
             parameters.&#xD;
&#xD;
          -  Subject is known to be hepatitis B, hepatitis C or HIV positive.&#xD;
&#xD;
          -  Subject has a diagnosis of bipolar disorder or current major depressive disorder, or&#xD;
             has any other medical or psychiatric condition, that in the investigator's opinion&#xD;
             would make the subject unsuitable for enrollment / participation in the study.&#xD;
&#xD;
          -  Subject has hepatic dysfunction defined as SGOT/AST or SGPT/ALT ≥ 2 times the upper&#xD;
             limit of normal (ULN) range, or alkaline phosphatase or total bilirubin ≥ 1.5 times&#xD;
             the ULN range or if in the opinion of the Investigator the subject's history, physical&#xD;
             examination or other laboratory tests suggest hepatic dysfunction.&#xD;
&#xD;
          -  Female subject who is pregnant, breast feeding, or if of childbearing potential, is&#xD;
             not using or is unwilling to use an effective form of contraception during the study&#xD;
             and for a period of 30 days following dosing.&#xD;
&#xD;
          -  Subject has known history of failure to respond to sumatriptan (ineffective or poorly&#xD;
             tolerated).&#xD;
&#xD;
          -  Subject has participated in a clinical study within 30 days of screening or is&#xD;
             planning to participate in another clinical study.&#xD;
&#xD;
          -  Subject has been previously enrolled in NP101-008.&#xD;
&#xD;
          -  Subject is electrically sensitive (e.g., prior iontophoresis with adverse outcome&#xD;
             related to the current delivered by the device) or who have electrically sensitive&#xD;
             support systems (e.g., pacemaker) or other medical condition that in the&#xD;
             investigator's opinion would make the subject unsuitable for enrollment in the study.&#xD;
&#xD;
          -  Subject who is considered by investigator or NuPathe, for any reason, to be an&#xD;
             unsuitable candidate for this study.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mark Pierce, M.D., PhD.</last_name>
    <role>Study Director</role>
    <affiliation>NuPathe Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Scottsdale</city>
        <state>Arizona</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Irvine</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Newport Beach</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Santa Monica</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Walnut Creek</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Fairfield</city>
        <state>Connecticut</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Hallandale Beach</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Ocala</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Sunrise</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Decatur</city>
        <state>Georgia</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Savannah</city>
        <state>Georgia</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Crestview Hills</city>
        <state>Kentucky</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>St. Louis</city>
        <state>Missouri</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Mount Vernon</city>
        <state>New York</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Plainview</city>
        <state>New York</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Greensboro</city>
        <state>North Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Oklahoma City</city>
        <state>Oklahoma</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Clarksville</city>
        <state>Tennessee</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Alexandria</city>
        <state>Virginia</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Virginia Beach</city>
        <state>Virginia</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2016</verification_date>
  <study_first_submitted>December 10, 2008</study_first_submitted>
  <study_first_submitted_qc>December 10, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 11, 2008</study_first_posted>
  <results_first_submitted>February 15, 2013</results_first_submitted>
  <results_first_submitted_qc>February 15, 2013</results_first_submitted_qc>
  <results_first_posted type="Estimate">March 20, 2013</results_first_posted>
  <disposition_first_submitted>November 7, 2012</disposition_first_submitted>
  <disposition_first_submitted_qc>February 6, 2013</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">February 7, 2013</disposition_first_posted>
  <last_update_submitted>February 2, 2016</last_update_submitted>
  <last_update_submitted_qc>February 2, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 4, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Migraine Disorders</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>The study was initiated March 2009 and completed in May 2011. Patients were enrolled from 34 investigative sites across the United States.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>NP101</title>
          <description>The NP101 patch contained 86 mg of sumatriptan and was designed to deliver approximately 6.5 mg of sumatriptan over 4 hours. Patients were asked to use study patches to treat migraine episodes with mild to severe headache pain for up to 12 months, during which they were permitted to apply (to the upper arms or thighs) a maximum of 6 patches within a 30-day period.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="514">35 subjects were enrolled but did not treat for a total of 479 subjects in the safety population</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="207"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="307"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Enrolled, not treated</title>
              <participants_list>
                <participants group_id="P1" count="35"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="32"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="74"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="75"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="49"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Various</title>
              <participants_list>
                <participants group_id="P1" count="42"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Patients were asked to use study patches to treat migraine episodes with mild to severe headache pain for up to 12 months. The safety population included all subjects who applied at least one NP101 patch. Of the 514 subjects enrolled, 35 subjects did not treat for a total of 479 subjects in the safety population.</population>
      <group_list>
        <group group_id="B1">
          <title>NP101</title>
          <description>The NP101 patch contained 86 mg of sumatriptan and was designed to deliver approximately 6.5 mg of sumatriptan over 4 hours. Patients were asked to use study patches to treat migraine episodes with mild to severe headache pain for up to 12 months, during which they were permitted to apply (to the upper arms or thighs) a maximum of 6 patches within a 30-day period.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="479"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="479"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="41.7" spread="11.85"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="392"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="87"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="479"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Subject Self-examination of Skin Irritation</title>
        <description>For each patch application, subjects performed a self-examination of skin irritation using a 5-point scale (0=no redness; 1=minimal skin redness; 2=moderate skin redness with sharp borders; 3=intense skin redness with or without swelling; 4=intense skin redness with blisters or broken skin).</description>
        <time_frame>24 hours post patch application</time_frame>
        <population>Per protocol, all subjects who applied at least one NP101 study patch were included in the safety population.</population>
        <group_list>
          <group group_id="O1">
            <title>NP101</title>
            <description>The NP101 patch contained 86 mg of sumatriptan and was designed to deliver approximately 6.5 mg of sumatriptan over 4 hours. Patients were asked to use study patches to treat migraine episodes with mild to severe headache pain for up to 12 months, during which they were permitted to apply (to the upper arms or thighs) a maximum of 6 patches within a 30-day period.</description>
          </group>
        </group_list>
        <measure>
          <title>Subject Self-examination of Skin Irritation</title>
          <description>For each patch application, subjects performed a self-examination of skin irritation using a 5-point scale (0=no redness; 1=minimal skin redness; 2=moderate skin redness with sharp borders; 3=intense skin redness with or without swelling; 4=intense skin redness with blisters or broken skin).</description>
          <population>Per protocol, all subjects who applied at least one NP101 study patch were included in the safety population.</population>
          <units>scores on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <units_analyzed>Participants</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="479"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>Patches</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7395"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.6" spread="0.86"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>All adverse events were collected from Screening until 30 days after the last study visit.</time_frame>
      <group_list>
        <group group_id="E1">
          <title>NP101</title>
          <description>The NP101 patch contained 86 mg of sumatriptan and was designed to deliver approximately 6.5 mg of sumatriptan over 4 hours. Patients were asked to use study patches to treat migraine episodes with mild to severe headache pain for up to 12 months, during which they were permitted to apply (to the upper arms or thighs) a maximum of 6 patches within a 30-day period.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA (10.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="479"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Atrial fibrillation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="479"/>
              </event>
              <event>
                <sub_title>Supraventricular tachycardia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="479"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>Goiter</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="479"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Bile duct stone</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="479"/>
              </event>
              <event>
                <sub_title>Cholelithiasis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="479"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="479"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="479"/>
              </event>
              <event>
                <sub_title>Syncope</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="479"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Pregnancy, puerperium and perinatal conditions</title>
            <event_list>
              <event>
                <sub_title>Ruptured ectopic pregnancy</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="479"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA (10.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="177" subjects_at_risk="479"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Application site discoloration</sub_title>
                <counts group_id="E1" events="28" subjects_affected="28" subjects_at_risk="479"/>
              </event>
              <event>
                <sub_title>Application site dryness</sub_title>
                <counts group_id="E1" events="27" subjects_affected="27" subjects_at_risk="479"/>
              </event>
              <event>
                <sub_title>Application site pain</sub_title>
                <counts group_id="E1" events="93" subjects_affected="93" subjects_at_risk="479"/>
              </event>
              <event>
                <sub_title>Application site paraesthesia</sub_title>
                <counts group_id="E1" events="26" subjects_affected="26" subjects_at_risk="479"/>
              </event>
              <event>
                <sub_title>Application site pruritus</sub_title>
                <counts group_id="E1" events="67" subjects_affected="67" subjects_at_risk="479"/>
              </event>
              <event>
                <sub_title>Application site reaction</sub_title>
                <counts group_id="E1" events="29" subjects_affected="29" subjects_at_risk="479"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Per the study agreement, Investigators shall have the right to publish or present information and/or data arising from the study, provided the text of any such publication or presentation is submitted for review at least thirty days prior to submission for publication or other disclosure and NuPathe shall have the right to request the removal of any confidential information</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Mark Pierce, MD, PhD</name_or_title>
      <organization>NuPathe Inc.</organization>
      <phone>484-567-0130</phone>
      <email>mpierce@nupathe.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

